By Notice dated August 19, 2003, and published in the Federal Register on September 2, 2003, (68 FR 52224), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration for registration as a bulk manufacturer of Dextropropoxyphene (9273), a basic class of Schedule II controlled substance.
The firm plans to manufacture bulk controlled substances for distribution to its customers.
No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the regulation of Cambrex Charles City, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state Start Printed Page 67474and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.Start Signature
Dated: November 19, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-29974 Filed 12-1-03; 8:45 am]
BILLING CODE 4410-09-M